Frequency of high risk human papillomavirus (HPV) serotypes in cervicovaginal smear of wives of men with genital warts and its relation with Pap smear

Document Type : Original Article


1 General PhD Student, Faculty of Medicine, Islamic Azad University of Mashhad, Mashhad, Iran.

2 Assistant Professor, Department of Dermatology, Faculty of Medicine, Islamic Azad University of Mashhad, Mashhad, Iran.

3 Assistant Professor, Department of Pathology, Faculty of Medicine, Islamic Azad University of Mashhad, Mashhad, Iran.

4 B.Sc. student of Nursing, School of Nursing, Islamic Azad University of Mashhad, Mashhad, Iran.


Introduction: Human papillomavirus is the leading cause of cervical cancer and with timely diagnosis and prompt treatment of these infections, the progression of cervical cancer can be prevented. This study was performed with aim to investigate the prevalence of high-risk human papillomavirus serotypes in cervicovaginal smears of wives of men with genital warts and its relation with Pap smear.
Methods: In this cross-sectional study, which was conducted between 2018 and 2020 in a private practice or affiliated clinics of the Islamic Azad University of Mashhad, 74 wives of men with genital warts were included in the study after confirmation of inclusion criteria. High-risk serotypes of human papillomavirus were determined by the Cobas apparatus, which is based on molecular methods. Cellular changes and inflammation of cervicovaginal smear samples were also examined by liquid base method in their spouses with genital warts. Data were analyzed using SPSS (version 20) and Kolmogorov-Smirnov, Chi-square, Fisher and ANOVA tests. P<0.05 was considered statistically significant.
Results: The prevalence of premalignancy lesions or low and high grade dysplasia in the wives of men with genital warts was 10.8% and 4.1%, respectively, while in 85.1% of the sample examined, no dysplasia was observed. Also, high-risk serotypes were observed in 29.7% of the wives of men with genital warts, that 8.1% were serotypes 16, 2.7% genotypes 18 and 18.9% other serotypes.
Conclusion: Due to the high prevalence of high-risk human papillomavirus in the wives of men with genital warts (29.7%), Pap smear test and determination of human papillomavirus serotype is recommended in these individuals.


  1. Qiao Y. Perspective of cervical cancer prevention and control in developing countries and areas. Chin J Cancer 2010; 29(1):1-3.
  2. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24:S11-25.
  3. Von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sexually Transmitted Infections 2000; 76(3):162-8.
  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359-86.
  5. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England journal of medicine 2003; 348(6):518-27.
  6. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. The lancet 2007; 370(9590):890-907.
  7. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infectious diseases in obstetrics and gynecology 2006; 2006.
  8. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC infectious diseases 2010; 10(1):1-7.
  9. Wrone DA. Clinical dermatology: A color guide to diagnosis and therapy. JAMA 2012; 307(14):1534.
  10. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, et al. Cervical cancer prevention: new tools and old barriers. Cancer: Interdisciplinary International Journal of the American Cancer Society 2010; 116(11):2531-42.
  11. Cooper CP, Saraiya M, Mclean TA, Hannan J, Liesmann JM, Rose SW, et al. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. Journal of Women's Health 2005; 14(8):670-8.
  12. van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. International journal of cancer 2008; 122(8):1854-8.
  13. Adampour Z, Hasanzadeh M, Zarrinfar H, Nakhaei M, Babi MN. Vaginitis Due to Pichia fermentans in a Patient Affected by Endometrial Cancer: A Novel Case Report. Current Women's Health Reviews 2022; 18(4):124-7.
  14. Minooeianhaghighi MH, Sehatpour M, Zarrinfar H, Sen T. Recurrent vulvovaginal candidiasis: the causative agents, clinical signs and susceptibility to fluconazole in Gonabad city, northeast Iran. Current Women's Health Reviews 2020; 16(1):46-51.
  15. Zarrinfar H, Kord Z, Fata A. High incidence of azole resistance among Candida albicans and C. glabrata isolates in Northeastern Iran. Current Medical Mycology 2021; 7(3):18-21.
  16. Gupta K, Malik NP, Sharma VK, Verma N, Gupta A. Prevalence of cervical dysplasia in western Uttar Pradesh. Journal of Cytology/Indian Academy of Cytologists 2013; 30(4):257-62.
  17. Ehdaeivand F, Neeknejad MT, Amini SN, Chiniforoush M. Cervix Dysplasia in 5000 Pap Smears in Ardabil. J Ardabil Univ Med Sci 2005; 5(1):22-25.
  18. Wang X, Zeng Y, Huang X, Zhang Y. Prevalence and genotype distribution of human papillomavirus in invasive cervical cancer, cervical intraepithelial neoplasia, and asymptomatic women in Southeast China. BioMed research international 2018; 2018.
  19. Jabbarpour Bonyadi M, Esmaeili M, Dasranj A. Determine the types of human papillomavirus oncogene multiplex PCR in cervical cancer lesions in North West of Iran. Article in Persian] J Infect Dis 2008; 13(41):29-34.
  20. Anic GM, Lee JH, Villa LL, Lazcano-Ponce E, Gage C, José C. Silva R, Baggio ML, Quiterio M, Salmerón J, Papenfuss MR, Abrahamsen M. Risk factors for incident condyloma in a multinational cohort of men: the HIM study. Journal of Infectious Diseases 2012; 205(5):789-93.
  21. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. The Lancet 2011; 377(9769):932-40.
  22. Mays RM, Zimet GD, Winston Y, Kee R, Dickes J, Su L. Human papillomavirus, genital warts, Pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health care for women international 2000; 21(5):361-74.